Arcus Biosciences’ quemliclustat receives US FDA orphan drug designation to treat pancreatic cancer: Hayward, California Tuesday, July 15, 2025, 13:00 Hrs [IST] Arcus Bioscience ...

The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is ...

Arcus Biosciences announced that the Food and Drug Administration has granted its pancreatic cancer treatment, quemliclustat, with an orphan drug designation. The company said it expects its ongoing ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

Quemliclustat is a potent and selective small molecule being developed by Arcus Biosciences. Inhibitor of CD73 that has been shown to block the production of adenosine.

Arcus Biosciences, a late-stage immuno-oncology company, is developing a diverse portfolio of assets, including casdatifan (cas), domvanalimab (dom), quemliclustat (quemli), and etrumadenant (etruma).

HAYWARD, Calif. - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company, announced today that it has secured a $250 million term loan facility with Hercules Capital, Inc ...

As a result of this option exercise, Taiho will operationalize the Phase 3 PRISM-1 study evaluating quemliclustat in pancreatic cancer in Japan, and Arcus will receive an opt-in payment and is ...

HAYWARD, Calif., August 08, 2024--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...